Mingkai Li, Zhi Zhang, Zebin Chen, Xi Chen, Huaqing Liu, Yuanqiang Xiao, Haimei Chen, Xiaodan Zong, Jingbiao Chen, Jianning Chen, Xinying Wang, Xuehong Xiao, Zhiwei Yang, Lanqing Han, Jin Wang, Bin Wu
下载PDF
{"title":"交互式可解释的深度学习模型在加多西酸增强MRI诊断肝细胞癌:一项回顾性,多中心,诊断研究。","authors":"Mingkai Li, Zhi Zhang, Zebin Chen, Xi Chen, Huaqing Liu, Yuanqiang Xiao, Haimei Chen, Xiaodan Zong, Jingbiao Chen, Jianning Chen, Xinying Wang, Xuehong Xiao, Zhiwei Yang, Lanqing Han, Jin Wang, Bin Wu","doi":"10.1148/rycan.240332","DOIUrl":null,"url":null,"abstract":"<p><p>Purpose To develop an artificial intelligence (AI) model based on gadoxetic acid-enhanced MRI to assist radiologists in hepatocellular carcinoma (HCC) diagnosis. Materials and Methods This retrospective study included patients with focal liver lesions (FLLs) who underwent gadoxetic acid-enhanced MRI between January 2015 and December 2021. All hepatic malignancies were diagnosed pathologically, whereas benign lesions were confirmed with pathologic findings or imaging follow-up. Five manually labeled bounding boxes for each FLL obtained from precontrast T1-weighted, T2-weighted, arterial phase, portal venous phase, and hepatobiliary phase images were included. The lesion classifier component, used to distinguish HCC from non-HCC, was trained and externally tested. The feature classifier, based on a post hoc algorithm, inferred the presence of the Liver Imaging Reporting and Data System (LI-RADS) features by analyzing activation patterns of the pretrained lesion classifier. Two radiologists categorized FLLs in the external testing dataset according to LI-RADS criteria. Diagnostic performance of the AI model and the model's impact on reader accuracy were assessed. Results The study included 839 patients (mean age, 51 years ± 12 [SD]; 681 male) with 1023 FLLs (594 HCCs and 429 non-HCCs). The AI model yielded area under the receiver operating characteristic curves of 0.98 and 0.97 in the training set and external testing set, respectively. Compared with LI-RADS category 5, the AI model showed higher sensitivity (91.6% vs 74.8%; <i>P</i> < .001) and similar specificity (90.7% vs 96.0%; <i>P</i> = .22). The two readers identified more LI-RADS major features and more accurately classified category LR-5 lesions when assisted versus unassisted by AI, with higher sensitivities (reader 1, 85.7% vs 72.3%; <i>P</i> < .001; reader 2, 89.1% vs 74.0%; <i>P</i> < .001) and the same specificities (reader 1, 93.3% vs reader 2, 94.7%; <i>P</i> > .99 for both). Conclusion The AI model accurately diagnosed HCC and improved the radiologists' diagnostic performance. <b>Keywords:</b> Artificial Intelligence, Deep Learning, MRI, Hepatocellular Carcinoma <i>Supplemental material is available for this article.</i> © RSNA, 2025 See also commentary by Singh et al in this issue.</p>","PeriodicalId":20786,"journal":{"name":"Radiology. Imaging cancer","volume":"7 3","pages":"e240332"},"PeriodicalIF":5.6000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130696/pdf/","citationCount":"0","resultStr":"{\"title\":\"Interactive Explainable Deep Learning Model for Hepatocellular Carcinoma Diagnosis at Gadoxetic Acid-enhanced MRI: A Retrospective, Multicenter, Diagnostic Study.\",\"authors\":\"Mingkai Li, Zhi Zhang, Zebin Chen, Xi Chen, Huaqing Liu, Yuanqiang Xiao, Haimei Chen, Xiaodan Zong, Jingbiao Chen, Jianning Chen, Xinying Wang, Xuehong Xiao, Zhiwei Yang, Lanqing Han, Jin Wang, Bin Wu\",\"doi\":\"10.1148/rycan.240332\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Purpose To develop an artificial intelligence (AI) model based on gadoxetic acid-enhanced MRI to assist radiologists in hepatocellular carcinoma (HCC) diagnosis. Materials and Methods This retrospective study included patients with focal liver lesions (FLLs) who underwent gadoxetic acid-enhanced MRI between January 2015 and December 2021. All hepatic malignancies were diagnosed pathologically, whereas benign lesions were confirmed with pathologic findings or imaging follow-up. Five manually labeled bounding boxes for each FLL obtained from precontrast T1-weighted, T2-weighted, arterial phase, portal venous phase, and hepatobiliary phase images were included. The lesion classifier component, used to distinguish HCC from non-HCC, was trained and externally tested. The feature classifier, based on a post hoc algorithm, inferred the presence of the Liver Imaging Reporting and Data System (LI-RADS) features by analyzing activation patterns of the pretrained lesion classifier. Two radiologists categorized FLLs in the external testing dataset according to LI-RADS criteria. Diagnostic performance of the AI model and the model's impact on reader accuracy were assessed. Results The study included 839 patients (mean age, 51 years ± 12 [SD]; 681 male) with 1023 FLLs (594 HCCs and 429 non-HCCs). The AI model yielded area under the receiver operating characteristic curves of 0.98 and 0.97 in the training set and external testing set, respectively. Compared with LI-RADS category 5, the AI model showed higher sensitivity (91.6% vs 74.8%; <i>P</i> < .001) and similar specificity (90.7% vs 96.0%; <i>P</i> = .22). The two readers identified more LI-RADS major features and more accurately classified category LR-5 lesions when assisted versus unassisted by AI, with higher sensitivities (reader 1, 85.7% vs 72.3%; <i>P</i> < .001; reader 2, 89.1% vs 74.0%; <i>P</i> < .001) and the same specificities (reader 1, 93.3% vs reader 2, 94.7%; <i>P</i> > .99 for both). Conclusion The AI model accurately diagnosed HCC and improved the radiologists' diagnostic performance. <b>Keywords:</b> Artificial Intelligence, Deep Learning, MRI, Hepatocellular Carcinoma <i>Supplemental material is available for this article.</i> © RSNA, 2025 See also commentary by Singh et al in this issue.</p>\",\"PeriodicalId\":20786,\"journal\":{\"name\":\"Radiology. Imaging cancer\",\"volume\":\"7 3\",\"pages\":\"e240332\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130696/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiology. Imaging cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1148/rycan.240332\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology. Imaging cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1148/rycan.240332","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
引用
批量引用